OBJECTIVES: HIV-1 reverse transcriptase (RT) mutations associated with antiviral drug resistance have been extensively characterized in the enzyme polymerase domain. Recent studies, however, have verified the involvement of the RT C-terminal domains (connection and RNase H) in drug resistance to RT inhibitors. In this work, we have characterized the correlation of recently described C-terminal domain mutations with thymidine analogue mutations (TAMs), as well as their phenotypic impact on susceptibility to zidovudine and nevirapine. METHODS: HIV-1 RT sequences from Brazilian patients and from public sequence databases for which the C-terminal RT domains and treatment status were also available were retrieved and analysed for the association of C-terminal mutations and the presence of TAMs and treatment status. Several C-terminal RT mutations previously characterized were introduced by site-directed mutagenesis into an HIV-1 subtype B molecular clone in a wild-type, TAM-1 or TAM-2 pathway context. Mutants were tested for drug susceptibility to the prototypic drugs zidovudine and nevirapine. RESULTS: Subtype B-infected patient database analysis showed that mutations N348I, A360V/T, T377M and D488E were found to be selected independently of TAMs, whereas mutations R358K, G359S, A371V, A400T, K451R and K512R increased in frequency with the number of TAMs in a dose-dependent fashion. Phenotypic analysis of C-terminal mutations showed that N348I, T369V and A371V conferred reduced susceptibility to zidovudine in the context of the TAM-1 and/or TAM-2 pathway, and also conferred dual resistance to nevirapine. Other mutations, such as D488E and Q547K, showed TAM-specific enhancement of resistance to zidovudine. Finally, mutation G359S displayed a zidovudine hypersusceptibility phenotype, both per se and when combined with A371V. CONCLUSIONS: This study demonstrates that distinct RT C-terminal mutations can act as primary or secondary drug resistance mutations, and are associated in a complex array of phenotypes with RT polymerase domain mutations.
OBJECTIVES:HIV-1 reverse transcriptase (RT) mutations associated with antiviral drug resistance have been extensively characterized in the enzyme polymerase domain. Recent studies, however, have verified the involvement of the RT C-terminal domains (connection and RNase H) in drug resistance to RT inhibitors. In this work, we have characterized the correlation of recently described C-terminal domain mutations with thymidine analogue mutations (TAMs), as well as their phenotypic impact on susceptibility to zidovudine and nevirapine. METHODS:HIV-1 RT sequences from Brazilian patients and from public sequence databases for which the C-terminal RT domains and treatment status were also available were retrieved and analysed for the association of C-terminal mutations and the presence of TAMs and treatment status. Several C-terminal RT mutations previously characterized were introduced by site-directed mutagenesis into an HIV-1 subtype B molecular clone in a wild-type, TAM-1 or TAM-2 pathway context. Mutants were tested for drug susceptibility to the prototypic drugs zidovudine and nevirapine. RESULTS: Subtype B-infected patient database analysis showed that mutations N348I, A360V/T, T377M and D488E were found to be selected independently of TAMs, whereas mutations R358K, G359S, A371V, A400T, K451R and K512R increased in frequency with the number of TAMs in a dose-dependent fashion. Phenotypic analysis of C-terminal mutations showed that N348I, T369V and A371V conferred reduced susceptibility to zidovudine in the context of the TAM-1 and/or TAM-2 pathway, and also conferred dual resistance to nevirapine. Other mutations, such as D488E and Q547K, showed TAM-specific enhancement of resistance to zidovudine. Finally, mutation G359S displayed a zidovudine hypersusceptibility phenotype, both per se and when combined with A371V. CONCLUSIONS: This study demonstrates that distinct RT C-terminal mutations can act as primary or secondary drug resistance mutations, and are associated in a complex array of phenotypes with RT polymerase domain mutations.
Authors: Galina N Nikolenko; Sarah Palmer; Frank Maldarelli; John W Mellors; John M Coffin; Vinay K Pathak Journal: Proc Natl Acad Sci U S A Date: 2005-01-31 Impact factor: 11.205
Authors: Bart Winters; Elke Van Craenenbroeck; Koen Van der Borght; Pierre Lecocq; Jorge Villacian; Lee Bacheler Journal: J Virol Methods Date: 2009-08-03 Impact factor: 2.014
Authors: Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka Journal: J Virol Date: 2008-01-23 Impact factor: 5.103
Authors: Jessica H Brehm; Dianna Koontz; Jeffrey D Meteer; Vinay Pathak; Nicolas Sluis-Cremer; John W Mellors Journal: J Virol Date: 2007-05-16 Impact factor: 5.103
Authors: Krista A Delviks-Frankenberry; Galina N Nikolenko; Frank Maldarelli; Saiki Hase; Yutaka Takebe; Vinay K Pathak Journal: J Virol Date: 2009-06-24 Impact factor: 5.103
Authors: Maryam Ehteshami; Greg L Beilhartz; Brian J Scarth; Egor P Tchesnokov; Suzanne McCormick; Brian Wynhoven; P Richard Harrigan; Matthias Götte Journal: J Biol Chem Date: 2008-06-10 Impact factor: 5.157
Authors: Maria F M Barral; Arielly K P Sousa; André F Santos; Celina M Abreu; Amilcar Tanuri; Marcelo A Soares Journal: AIDS Res Hum Retroviruses Date: 2016-12-27 Impact factor: 2.205
Authors: Maria E Cilento; Aaron B Reeve; Eleftherios Michailidis; Tatiana V Ilina; Eva Nagy; Hiroaki Mitsuya; Michael A Parniak; Philip R Tedbury; Stefan G Sarafianos Journal: Antimicrob Agents Chemother Date: 2021-09-13 Impact factor: 5.191
Authors: Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak Journal: Virology Date: 2012-10-13 Impact factor: 3.616
Authors: Isabel M Prellwitz; Brunna M Alves; Maria Letícia R Ikeda; Daniele Kuhleis; Pedro D Picon; Carla A Jarczewski; Marta R Osório; Alexandra Sánchez; Héctor N Seuánez; Bernard Larouzé; Marcelo A Soares; Esmeralda A Soares Journal: PLoS One Date: 2013-07-09 Impact factor: 3.240